Frontiers in Cardiovascular Medicine (Jan 2022)

Mitochondria in Pathological Cardiac Hypertrophy Research and Therapy

  • Dan Yang,
  • Dan Yang,
  • Han-Qing Liu,
  • Fang-Yuan Liu,
  • Fang-Yuan Liu,
  • Zhen Guo,
  • Zhen Guo,
  • Peng An,
  • Peng An,
  • Ming-Yu Wang,
  • Ming-Yu Wang,
  • Zheng Yang,
  • Zheng Yang,
  • Di Fan,
  • Di Fan,
  • Qi-Zhu Tang,
  • Qi-Zhu Tang

DOI
https://doi.org/10.3389/fcvm.2021.822969
Journal volume & issue
Vol. 8

Abstract

Read online

Cardiac hypertrophy, a stereotypic cardiac response to increased workload, ultimately progresses to severe contractile dysfunction and uncompensated heart failure without appropriate intervention. Sustained cardiac overload inevitably results in high energy consumption, thus breaking the balance between mitochondrial energy supply and cardiac energy demand. In recent years, accumulating evidence has indicated that mitochondrial dysfunction is implicated in pathological cardiac hypertrophy. The significant alterations in mitochondrial energetics and mitochondrial proteome composition, as well as the altered expression of transcripts that have an impact on mitochondrial structure and function, may contribute to the initiation and progression of cardiac hypertrophy. This article presents a summary review of the morphological and functional changes of mitochondria during the hypertrophic response, followed by an overview of the latest research progress on the significant modulatory roles of mitochondria in cardiac hypertrophy. Our article is also to summarize the strategies of mitochondria-targeting as therapeutic targets to treat cardiac hypertrophy.

Keywords